Academic Journal
Q2Bioorganic & Medicinal Chemistry Letters
About Bioorganic & Medicinal Chemistry Letters
Bioorganic & Medicinal Chemistry Letters is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q2 with an SJR of 0.426 and an H-index of 177.
Its listed coverage is 1991-2026 and its research categories include Pharmaceutical Science (Q2); Biochemistry (Q3); Clinical Biochemistry (Q3); Drug Discovery (Q3); Organic Chemistry (Q3); Molecular Biology (Q4); Molecular Medicine (Q4). The 2025 dataset reports 259 documents and 2324 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Chemical Synthesis and Analysis, Synthesis and biological activity, Receptor Mechanisms and Signaling, Synthesis and Biological Evaluation, Click Chemistry and Applications, Cancer therapeutics and mechanisms.
Recent Research Articles
Latest publications matched automatically by ISSN.
6-(2-Hydroxybenzoyl)pyrazolo[1,5-a]pyrimidine-3‑carbonitriles as novel reactive oxygen species-generating anticancer agents inducing ER stress and DNA damage in EGFR-mutant non-small cell lung cancer
Ji Yun Baek, Seunghyun Ahn, HeeWon Kang, Euitaek Jung et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130775Semi-synthesis and activity study of α-mangostin ether derivatives bearing N-heterocyclic side chains as multitarget-directed ligands against AD
Bokai Zhang, Yu Li, Xiaoli Qiao, Boyong Zhang et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130758Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections
Marie Gréverie, Alexandra Dassonville-Klimpt, Morgane Choquet, Claire Andréjak et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130781Efficient PNA double-duplex invasion using preQ1•G-clamp as a pseudo-complementary G•C base pair
Yuga Shibuya, Yosuke Demizu, Toru Sugiyama
2027-01 · DOI: 10.1016/j.bmcl.2026.130776Discovery of novel dual STAT3/TrxR1 inhibitors via pharmacophore fusion as potent lead compounds for colorectal cancer
Yigui Li, Rui Xu, Xinhua Xie, Wanzhu Zhao et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130777Amyloid-β aggregation inhibitory activity and neuroprotective effects of metabolites of Trichoderma pluripenicillatum
Hayato Yoshikawa, Takahiro Matsumoto, Emi Yoshida, Tomoe Ohta et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130778Reactivation of an inert 15-mer antimicrobial peptide by truncation-directed i, i + 7 lactam cyclization
Jinhua Zhang, Zhiyi Jiang, Mingli Jiang, Zhuoqiong Guo et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130763Synthesis and antimalarial activity of novel C30-aminated betulin derivatives
Christopher Bérubé, Catherine Bergeron, Dominic Gagnon, Mathieu Gagné-Boulet et al.
2027-01 · DOI: 10.1016/j.bmcl.2026.130760Contents continued
2026-12 · DOI: 10.1016/s0960-894x(26)00241-6Development of karapinchamine A-related carbazoles with antiproliferative activity against glioblastoma-derived cancer stem cells and blood–brain barrier permeability
Haruka Kawatake, Sakura Ichioka, Yutaro Ohki, Kouta Ugawa et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130745Caffeic acid phenethyl ester derivatives inhibit glyoxalase I activity and induce cell death in cultured cancer cell lines
Shuji Ishizaki, Aya Nishida, Kanako Nakamine, Kana Yamaji et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130762Novel salicylamido sulfonamides as CD73 immune checkpoint inhibitors: Synthesis and in vitro biological evaluation
Dinesh Krishna Narukulla, Shrilekha Chilvery, Chandraiah Godugu, Avvaru Subha Jahnavi et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130756Editorial Board
2026-12 · DOI: 10.1016/s0960-894x(26)00235-0Discovery of orally available benzimidazole-based STING antagonists with in vivo activity
Takao Kiyoi, Hirokazu Matsumoto, Shiori Takamatsu, Haruka Taniguchi et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130757Retraction notice to “Rational design and translational advancement of phospholipid-based nanocarriers for targeted cancer therapy” [Bioorg. Med. Chem. Lett. 129 (2025) 130396]
Kateryna Mykhailivna Doroshenko, Oleksander Ivanovich Shefchenko
2026-12 · DOI: 10.1016/j.bmcl.2026.130746Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy
Yixue Han, Ruiqi Wang, Lina Tian, Jian Xiao et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130747Graphical abstract TOC
2026-12 · DOI: 10.1016/s0960-894x(26)00237-4Design, synthesis, and evaluation of novel 5-aminolevulinic acid and 3-hydroxypyridinone conjugates for enhanced photodynamic therapy in triple-negative breast cancer
Jinhui Ren, Jingqi Zhang, Yan Liu, Yikai Shen et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130759Erratum to “Development of a novel PI3Kα/CDK7 potent hybrid inhibitor for Cancer treatment” [Bioorg. Med. Chem. Lett. 140 (2026) 130738]
Ghassan M. Abushaikha, Tyler J. Chitwood, Abdel Bayazid, Negin Abdollahi et al.
2026-12 · DOI: 10.1016/j.bmcl.2026.130748Graphical abstract TOC
2026-12 · DOI: 10.1016/s0960-894x(26)00236-2Reviews
Community Reviews
Version History
September 8, 2026 at 12:03 am
September 8, 2026